Evaluation of the efficacy of outer membrane protein 31 vaccine formulations for protection against Brucella canis in BALB/c mice

Canine brucellosis is an infectious disease caused by the Gram-negative bacterium Brucella canis. Unlike conventional control programs for other species of the genus Brucella, currently there is no vaccine available against canine brucellosis, and preventive measures are simply diagnosis and isolati...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and vaccine immunology 2014-12, Vol.21 (12), p.1689-1694
Main Authors: Clausse, Maria, Díaz, Alejandra G, Ibañez, Andrés E, Cassataro, Juliana, Giambartolomei, Guillermo H, Estein, Silvia M
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Animals
Antibodies, Bacterial - blood
Bacterial Outer Membrane Proteins - immunology
Brucella
Brucella canis
Brucella canis - immunology
Brucella Vaccine - immunology
Brucellosis - immunology
Brucellosis - prevention & control
Canis
Dogs
Mice
Mice, Inbred BALB C
T-Lymphocytes, Cytotoxic - immunology
Vaccination
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Canine brucellosis is an infectious disease caused by the Gram-negative bacterium Brucella canis. Unlike conventional control programs for other species of the genus Brucella, currently there is no vaccine available against canine brucellosis, and preventive measures are simply diagnosis and isolation of infected dogs. New approaches are therefore needed to develop an effective and safe immunization strategy against this zoonotic pathogen. In this study, BALB/c mice were subcutaneously immunized with the following: (i) the recombinant Brucella Omp31 antigen formulated in different adjuvants (incomplete Freund adjuvant, aluminum hydroxide, Quil A, and Montanide IMS 3012 VGPR), (ii) plasmid pCIOmp31, or (iii) pCIOmp31 plasmid followed by boosting with recombinant Omp31 (rOmp31). The immune response and the protective efficacy against B. canis infection were characterized. The different strategies induced a strong immunoglobulin G (IgG) response. Furthermore, spleen cells from rOmp31-immunized mice produced gamma interferon and interleukin-4 (IL-4) after in vitro stimulation with rOmp31, indicating the induction of a mixed Th1-Th2 response. Recombinant Omp31 administered with different adjuvants as well as the prime-boost strategy conferred protection against B. canis. In conclusion, our results suggest that Omp31 could be a useful candidate for the development of a subcellular vaccine against B. canis infection.
ISSN:1556-6811
1556-679X
DOI:10.1128/CVI.00527-14